Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide

Phoebe A. Huang, Shaunna L. Beedie, Cindy H. Chau, David J. Venzon, Sheryl Gere, Dickran Kazandjian, Neha Korde, Sham Mailankody, Ola Landgren, William D. Figg*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Carfilzomib-lenalidomide-dexamethasone (KRd) therapy has yielded promising results in patients with newly diagnosed multiple myeloma (NDMM). Cereblon (CRBN) is the direct molecular target of lenalidomide and genetic polymorphisms in CRBN have been associated with lenalidomide efficacy. In this study, we assessed the correlation of five single nucleotide variants (SNVs) in the CRBN gene with clinical response and outcomes in patients with NDMM administered KRd therapy with lenalidomide maintenance, achieving favorable trial endpoints in a prospective Phase II study (NCT01402284). Of the observed SNVs, no associations with KRd therapy response were found in this patient cohort, although strong trends in hypoalbuminemia grade and hyperbilirubinemia grade emerged across the CRBN rs1672753 genotype (P = 0.0008) and the rs1714327 genotype (P = 0.0010), respectively. Our results do not provide conclusive support for the predictive utility of CRBN gene polymorphisms as potential biomarkers of clinical response to lenalidomide-based therapy in our patient population. However, these findings remain to be validated in prospective studies using larger patient populations.

Original languageEnglish
Article number14884
JournalScientific Reports
Issue number1
StatePublished - 1 Dec 2019
Externally publishedYes


Dive into the research topics of 'Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide'. Together they form a unique fingerprint.

Cite this